Clinical trials: Human Cancers
Advanced Solid Tumor
First in Human Study of T3P-Y058-739 (T3P)
This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with…
- Trial name
- NCT05120596
- Testing
- Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 100 people
- Sponsor
- T3 Pharmaceuticals AG
Neoplasms,Ovarian
Urinary Human Papilloma Virus Test in the General Population in Brittany
This is a population-based, prospective, multicenter and open-label study. 12,500 female non-respondents to the uterine cervix smear from 30 to 65 years of age in the context of the organized cervical cancer screening of the…
- Trial name
- PapU-Access (NCT03598946)
- Testing
- Urinary test
- Where
- France
- Volunteers
- 1,809 people
- Sponsor
- University Hospital, Brest
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Oropharyngeal Cancer
Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma
Cancer of the oropharynx (middle, side and back walls of the throat; back of the tongue; soft palate, and tonsils), or oropharyngeal squamous cell carcinoma (OPSCC), has been on the rise in the United States.
- Trial name
- NCT02147418
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Prostate Cancer, Prostate Cancer Metastatic Disease
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer
- Trial name
- PR3DICT (NCT07004582)
- Testing
- HDR brachytherapy, Diagnostic biopsy
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht Radiation Oncology
Metastasis From Malignant Melanoma of Skin (Diagnosis)
Irradiation of Melanoma in a Pulse
This is a single center phase I, first-in-human, dose escalation study of FLASH therapy in patients with metastases of melanoma.
- Trial name
- IMPulse (NCT04986696)
- Testing
- FLASH therapy
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Prospective Study of Lymphoproliferative Diseases
This study will help researchers learn more about non-Hodgkin's lymphoma and Hodgkin's lymphoma and how it is treated in Kenya. Researchers want to see if having certain viruses like Epstein Barr Virus (EBV), Human…
- Trial name
- NCT01704742
- Where
- 2 sites in United States, Kenya
- Sponsor
- West Virginia University
Head and Neck Cancer, Infection
Oral HPV Infection in Young Men
RATIONALE: Gathering information about human papillomavirus infection of the mouth in young men may help doctors learn more about risk factors for oropharyngeal cancer.
- Conditions
- Head and Neck Cancer, Infection, Precancerous Condition
- Trial name
- NCT00897273
- Testing
- comparative genomic hybridization, gene expression analysis, study of socioeconomic and demographic variables
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-negative Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04836156
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood.
- Conditions
- Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells
- Trial name
- TREAT-CTC (NCT01548677)
- Testing
- trastuzumab
- Where
- 80 sites in Belgium, France and 2 more
- Volunteers
- 1,317 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Patients With Multiple Myeloma Experiencing a, First or Second Relapse
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
- Trial name
- KIRIMID (NCT01217203)
- Testing
- IPH2101 combined to lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Innate Pharma
Hepatitis C Virus Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer…
- Trial name
- NCT02868242
- Testing
- LDV/SOF
- Where
- Egypt
- Volunteers
- 19 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumor
Dose Escalation Study of Immunomodulatory Nanoparticles
PRECIOUS-01 is an immunomodulating agent composed of the invariant natural killer T cell (iNKT) activator threitolceramide-6 (ThrCer6, IMM60) and the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer-testis antigen…
- Trial name
- PRECIOUS-01 (NCT04751786)
- Testing
- PRECIOUS-01
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Non-Small-Cell Lung Carcinoma
Celecoxib Treatment for Lung Cancer
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer.
- Trial name
- NCT00108186
- Testing
- Celecoxib
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Advanced Solid Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors
To assess the safety, tolerability, PK and preliminary efficacy of CD-001 in patients with advanced solid tumors. and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT06801470
- Testing
- CD-001
- Where
- China
- Volunteers
- 137 people
- Sponsor
- CD (Suzhou) Biopharma Co., Ltd.
Breast Neoplasms, Breast Cancer
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with…
- Conditions
- Breast Neoplasms, Breast Cancer, Cancer of the Breast
- Trial name
- NCT01272141
- Testing
- Lapatinib and Everolimus
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
To evaluate the efficacy and safety of Endostar combined with concurrent chemo-radiotherapy (CCRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
- Trial name
- DP-EN-RT (NCT01218594)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Human Immunodeficiency Virus, Human Papillomavirus
Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya
The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to improve Human papillomavirus…
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus, Cervical Precancer
- Trial name
- NCT06519994
- Testing
- Artesunate vaginal inserts
- Where
- Kenya
- Volunteers
- 120 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual…
- Trial name
- ESCAPE (NCT02194166)
- Testing
- Trastuzumab, Paclitaxel, Docetaxel
- Where
- 7 sites in Belarus, Kazakhstan
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.